Neurosarcoidosis: Longitudinal Experience in a Single-Center, Academic Health Care System (P1.2-046)

Objective: Describe the demographics and clinical characteristics including age of onset of disease, laboratory evaluation, imaging findings, treatment, and long term outcomes of patients within the University of Utah Healthcare system with neurosarcoidosis and immune-mediated granulomatous disease affecting the central nervous system. Background: The clinical phenotypes associated with neurosarcoidosis are diverse although it most commonly presents with cranial neuropathy or meningeal involvement. There is a paucity of literature regarding epidemiological data on patients with neurosarcoidosis. To date, neurosarcoidosis remains without any FDA-approved therapies, leaving physicians with limited guidance for optimal treatment regimens, and even less data on patient outcomes. Design/Methods: We performed a retrospective review of patients within the University of Utah Healthcare system meeting the following criteria: At least one ICD-9-CM code 135 or ICD-10-CM code D86* (sarcoidosis) At least one visit with a University of Utah clinician in the Neurology Department within the University of Utah electronic health record. Results: We identified patients meeting the above criteria and characterized them with relevant demographics and clinical data including age at symptom onset, age at diagnosis, associated neurological symptoms, associated autoimmunity and malignancy, and response to symptomatic therapy and/or immunotherapy. Conclusions: This is a comprehensive characterization of neurosarcoidosis within a single health care system at the University of Utah that reports on the long-term response to treatment and outcomes of neurosarcoidosis patients. Disclosure: Dr. Lord has nothing to disclose. Dr. Bacharach has nothing to disclose. Dr. Galli has nothing to disclose. Dr. Kresser has nothing to disclose. Dr. Klein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva and Biogen Idec. Dr. DeWitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Paz Soldan has received research support from Biogen. Dr. Rose has received research support from the National Multiple Sclerosis Society, the Guthy Jackson Foundation, the Western Institute for Biomedical Research, Teva Neuroscience and Biogen. Dr. Greenlee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Wheeler, Trigg, and O’Donnell. Dr. Greenlee has received personal compensation in an editorial capacity for Medlink and Merck Manual, Professional and Home. Dr. Clardy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adivo Associates (